U.S. High Court Lets Reversal Of Avandia Preemption Ruling By 3rd Circuit Stand

Mealey's (October 8, 2020, 12:33 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 5 denied a certiorari petition by GlaxoSmithKline LLC (GSK) to reverse a preemption ruling involving the diabetes drug Avandia based on an interpretation by the Third Circuit U.S. Court of Appeals of a 2019 Supreme Court preemption decision (GlaxoSmithKline LLC v. United Food and Commercial Workers Local 1776, et al., No. 19-1444, U.S. Sup.)....

Attached Documents

Related Sections